Scinai Immunotherapeutics Stock Performance
| SCNI Stock | USD 3.35 0.05 1.47% |
The entity has a beta of 0.46, which indicates possible diversification benefits within a given portfolio. As returns on the market increase, Scinai Immunotherapeuti's returns are expected to increase less than the market. However, during the bear market, the loss of holding Scinai Immunotherapeuti is expected to be smaller as well. At this point, Scinai Immunotherapeutics has a negative expected return of -0.0659%. Please make sure to validate Scinai Immunotherapeuti's sortino ratio, skewness, period momentum indicator, as well as the relationship between the potential upside and rate of daily change , to decide if Scinai Immunotherapeutics performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Scinai Immunotherapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. Despite fairly strong basic indicators, Scinai Immunotherapeuti is not utilizing all of its potentials. The current stock price confusion, may contribute to short-horizon losses for the traders. ...more
Actual Historical Performance (%)
One Day Return 0.6 | Year To Date Return (45.08) | Ten Year Return (99.33) | All Time Return (99.33) |
Last Split Factor 1:10 | Last Split Date 2024-05-21 |
1 | Scinai Publishes Financial Results and Provides Business Update Shareholders Equity up from negative 7.3 million as of June 30, 2024, to positive 10 million | 11/22/2024 |
2 | Dr. Jonathan Sadeh, Former Senior Vice President of Immunology RD at Bristol-Myers Squibb, Joins Scinai Immunotherapeutics Scientific Advisory Board | 11/27/2024 |
3 | Scinai Immunotherapeutics Welcomes Dr. Jonathan Sadeh to Scientific Advisory Board - Barchart | 12/02/2024 |
4 | Scinai Immunotherapeutics Establishes U.S. Subsidiary for CDMO Business Unit, Scinai Bioservices Inc. | 12/16/2024 |
| Begin Period Cash Flow | 14.2 M |
Scinai |
Scinai Immunotherapeuti Relative Risk vs. Return Landscape
If you would invest 364.00 in Scinai Immunotherapeutics on September 27, 2024 and sell it today you would lose (29.00) from holding Scinai Immunotherapeutics or give up 7.97% of portfolio value over 90 days. Scinai Immunotherapeutics is currently does not generate positive expected returns and assumes 3.7094% risk (volatility on return distribution) over the 90 days horizon. In different words, 33% of stocks are less volatile than Scinai, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Scinai Immunotherapeuti Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Scinai Immunotherapeuti's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Scinai Immunotherapeutics, and traders can use it to determine the average amount a Scinai Immunotherapeuti's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0178
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | SCNI |
Estimated Market Risk
| 3.71 actual daily | 33 67% of assets are more volatile |
Expected Return
| -0.07 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.02 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Scinai Immunotherapeuti is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Scinai Immunotherapeuti by adding Scinai Immunotherapeuti to a well-diversified portfolio.
Scinai Immunotherapeuti Fundamentals Growth
Scinai Stock prices reflect investors' perceptions of the future prospects and financial health of Scinai Immunotherapeuti, and Scinai Immunotherapeuti fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Scinai Stock performance.
| Return On Asset | -0.28 | ||||
| Operating Margin | (7.14) % | ||||
| Current Valuation | 10.13 B | ||||
| Shares Outstanding | 853 K | ||||
| Price To Book | 0.65 X | ||||
| Price To Sales | 10.06 X | ||||
| EBITDA | (9.19 M) | ||||
| Net Income | (6.5 M) | ||||
| Cash And Equivalents | 13.45 K | ||||
| Total Debt | 20.56 M | ||||
| Current Ratio | 0.16 X | ||||
| Book Value Per Share | (9.84) X | ||||
| Cash Flow From Operations | (9.38 M) | ||||
| Earnings Per Share | 2.40 X | ||||
| Market Capitalization | 2.86 M | ||||
| Total Asset | 17.47 M | ||||
| Retained Earnings | (122.33 M) | ||||
| Working Capital | 3.67 M | ||||
| Current Asset | 143 K | ||||
| Current Liabilities | 907 K | ||||
About Scinai Immunotherapeuti Performance
By evaluating Scinai Immunotherapeuti's fundamental ratios, stakeholders can gain valuable insights into Scinai Immunotherapeuti's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Scinai Immunotherapeuti has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Scinai Immunotherapeuti has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 0.00 | 0.01 | |
| Return On Tangible Assets | (0.37) | (0.39) | |
| Return On Capital Employed | (0.62) | (0.65) | |
| Return On Assets | (0.37) | (0.39) | |
| Return On Equity | 1.42 | 1.49 |
Things to note about Scinai Immunotherapeutics performance evaluation
Checking the ongoing alerts about Scinai Immunotherapeuti for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Scinai Immunotherapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Scinai Immunotherapeuti generated a negative expected return over the last 90 days | |
| Scinai Immunotherapeuti has high historical volatility and very poor performance | |
| Scinai Immunotherapeuti has a very high chance of going through financial distress in the upcoming years | |
| Scinai Immunotherapeutics currently holds 20.56 M in liabilities. Scinai Immunotherapeutics has a current ratio of 0.16, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Note, when we think about Scinai Immunotherapeuti's use of debt, we should always consider it together with its cash and equity. | |
| Net Loss for the year was (6.5 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Scinai Immunotherapeutics currently holds about 13.45 K in cash with (9.38 M) of positive cash flow from operations. | |
| Scinai Immunotherapeuti has a very weak financial position based on the latest SEC disclosures | |
| Roughly 13.0% of the company outstanding shares are owned by corporate insiders | |
| Latest headline from finance.yahoo.com: Scinai Immunotherapeutics Establishes U.S. Subsidiary for CDMO Business Unit, Scinai Bioservices Inc. |
- Analyzing Scinai Immunotherapeuti's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Scinai Immunotherapeuti's stock is overvalued or undervalued compared to its peers.
- Examining Scinai Immunotherapeuti's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Scinai Immunotherapeuti's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Scinai Immunotherapeuti's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Scinai Immunotherapeuti's stock. These opinions can provide insight into Scinai Immunotherapeuti's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Scinai Stock analysis
When running Scinai Immunotherapeuti's price analysis, check to measure Scinai Immunotherapeuti's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Scinai Immunotherapeuti is operating at the current time. Most of Scinai Immunotherapeuti's value examination focuses on studying past and present price action to predict the probability of Scinai Immunotherapeuti's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Scinai Immunotherapeuti's price. Additionally, you may evaluate how the addition of Scinai Immunotherapeuti to your portfolios can decrease your overall portfolio volatility.
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Commodity Directory Find actively traded commodities issued by global exchanges |